Indications and Approved Uses

  • To reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure, Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal.
  • For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in paediatric patients aged one year and older. This combination reduces NT-proBNP and is expected to improve cardiovascular outcomes